RESEARCH ARTICLE

**Exposure to parasitic infections determines features and phenotypes of active convulsive epilepsy in Africa**

*version 2; peer review: 1 approved, 1 approved with reservations*

Nelson K. Langat¹,², Symon M. Kariuki¹,³,⁴, Gathoni Kamuyu¹, Angelina Kakooza-Mwesige⁵, Seth Owusu-Agyei⁶,⁷, Kenneth Ae-Ngibise¹⁰, Anne Wang’ombe², Anthony K. Ngugi⁸, Honorati Masaja⁹, Ryan G. Wagner¹⁰, Charles R.J.C. Newton¹,³,⁴, on behalf of the Study of Epidemiology of Epilepsy in Demographic Sites (SEEDS) group

¹Clinical-Neurosciences, Kenya Medical Research Institute (KEMRI)/Wellcome Trust Research Programme, Kilifi, Kenya
²Institute of Tropical and Infectious Diseases, University of Nairobi, Nairobi, Kenya
³Department of Public health, Pwani University, Kilifi, Kenya
⁴Department of Psychiatry, University of Oxford, Oxford, UK
⁵Department of Paediatrics and Child Health, Makerere University College of Health Sciences, Kampala, Uganda
⁶Kintampo Health Research Centre, Kintampo, Ghana
⁷Institute of Health Research, University of Health and Allied Sciences, Ho, Ghana
⁸Department of Population Health, Medical College (East Africa), Aga Khan University, Nairobi, Kenya
⁹Ifakara Health Institute, Ifakara, Tanzania
¹⁰MRC/Wits Rural Public Health & Health Transitions Research Unit (Agincourt), School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

First published: 05 Aug 2021, 6:200
https://doi.org/10.12688/wellcomeopenres.17049.1
Latest published: 22 Jun 2022, 6:200
https://doi.org/10.12688/wellcomeopenres.17049.2

**Abstract**

**Background:** Epilepsy affects 70 million people worldwide, 80% of whom are in low-and-middle income countries (LMICs). Parasitic infections contribute considerably to the burden of epilepsy in LMICs, but the nature and presentation of epilepsy following these infections is not fully understood. We examined if epilepsy outcomes are associated with the exposure to parasitic infections.

**Methods:** This was a case-comparison study nested in a cross-sectional survey of people with active convulsive epilepsy, with cases as those exposed to parasitic infections, and comparison as those unexposed. Examination of exposure to parasites with clinical and electroencephalographic features of epilepsy were done using a modified mixed effects Poisson regression model across five sites in Africa. Multiplicative and additive scale (RERI) interactions were...
explored to determine the effect of co-infections on epilepsy features. Population attributable fractions (PAF) were calculated to determine the proportion of severe clinical and electroencephalographic features of epilepsy attributable to parasitic infections.

Results: A total of 997 participants with active convulsive epilepsy from the five African sites were analyzed, 51% of whom were males. Exposure to parasitic infections was associated with more frequent seizures in adult epilepsy (relative risk (RR)=2.58, 95% confidence interval (95%CI):1.71-3.89). In children, exposure to any parasite was associated with convulsive status epilepticus (RR=4.68, (95%CI: 3.79-5.78), intellectual disabilities (RR=2.13, 95%CI: 1.35-3.34) and neurological deficits (RR=1.92, 95%CI: 1.42-2.61). *Toxoplasma gondii* and *Onchocerca volvulus* interacted synergistically to increase the risk of status epilepticus (RERI=0.91, 95%CI=0.48-1.35) in the data pooled across the sites. Exposure to parasitic infections contributed to 30% of severe features of epilepsy as shown by PAF.

Conclusions: Parasitic infections may determine features and phenotypes of epilepsy through synergistic or antagonistic interactions, which can be different in children and adults. Interventions to control or manage infections may reduce complications and improve prognosis in people with epilepsy.

Keywords
Epilepsy, parasitic infections, status epilepticus, neurologic deficits, intellectual disabilities, seizures, Africa
Corresponding author: Symon M. Kariuki (skariuki@kemri-wellcome.org)

Author roles: Langat NK: Data Curation, Formal Analysis, Methodology, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing; Kariuki SM: Conceptualization, Data Curation, Formal Analysis, Methodology, Supervision, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing; Kamuyu G: Investigation, Methodology, Project Administration, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing; Kakooza-Mwesige A: Methodology, Project Administration, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing; Owusu-Agyei S: Methodology, Project Administration, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing; Ae-Ngibise K: Methodology, Project Administration, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing; Wang’ombe A: Methodology, Supervision, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing; Masaja H: Methodology, Project Administration, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing; Newton CRJC: Conceptualization, Formal Analysis, Funding Acquisition, Investigation, Methodology, Project Administration, Supervision, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing;

Competing interests: No competing interests were disclosed.

Grant information: This work was supported by the Wellcome Trust [083744, https://doi.org/10.35802/083744, 099782; https://doi.org/10.35802/099782, Wellcome Trust Senior Fellowships in Clinical Tropical Medicine to CRN and Research Training Fellowship to SMK, respectively]. SMK is supported by MQ: Transforming Mental Health (MQF17-18) and by the EDCTP2 programme supported by the European Union (TMA2017CDF-1903). This work was also supported by the African Academy of Sciences (AAS) through a DELTAS Africa Initiative grant awarded to Nelson Langat [DEL-15-003]. The DELTAS Africa Initiative is an independent funding scheme of the AAS’s Alliance for Accelerating Excellence in Science in Africa (AESA) and supported by the New Partnership for Africa’s Development Planning and Coordinating Agency (NEPAD Agency) with funding from the Wellcome Trust [107769] and the UK government. The views expressed in this publication are those of the author(s) and not necessarily those of AAS, NEPAD Agency, Wellcome Trust or the UK government.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2022 Langat NK et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Langat NK, Kariuki SM, Kamuyu G et al. Exposure to parasitic infections determines features and phenotypes of active convulsive epilepsy in Africa [version 2; peer review: 1 approved, 1 approved with reservations] Wellcome Open Research 2022, 6:200 https://doi.org/10.12688/wellcomeopenres.17049.2

First published: 05 Aug 2021, 6:200 https://doi.org/10.12688/wellcomeopenres.17049.1
Epilepsy is a common serious neurological disorder, with an estimated 70 million people being affected, 90% of whom live in low-and-middle-income countries (LMICs) (Ngugi et al., 2010). Global incidence of epilepsy is up to 278 per 100,000 people, while global prevalence is up to 11 per 1,000 people (Fiest et al., 2017), with both incidence and prevalence being higher in LMICs than high-income countries (HICs) (Newton & Garcia, 2012). The higher burden of epilepsy in LMICs can be attributed to the higher incidence of infections such as malaria and human immunodeficiency virus (HIV), birth-related injuries and low accessibility to health care (Newton & Garcia, 2012).

A study carried out in selected African populations indicated that exposure to multiple parasites was associated with the risk of epilepsy (Kamuyu et al., 2014). However, this study did not determine the contribution of infections to features and phenotypes of epilepsy and examine response to anti-seizure medications (ASM) (Kariuki et al., 2014). It is important to describe the features and phenotypes of epilepsy ascribable to exposure to infections since most infections are preventable through simple public health interventions. Infections such as malaria and HIV can increase the risk for status epilepticus (Kariuki et al., 2015) and frequent seizures, both of which worsen prognosis of epilepsy. Early onset epilepsy, which is common in Africa, may be caused by infections, which affects children because of undeveloped immunity and brain. Infections may also damage the brain resulting in comorbidities of severe epilepsy such as intellectual disability and neurological deficits, which can affect adherence to ASM (Ibinda et al., 2017; Mbuba et al., 2012). Additionally, exposure to infections may complicate biomedical treatment of epilepsy. It important to determine the burden of severe epilepsy that could be prevented by control of infections. Findings from such studies may be useful in informing policymakers on the impact that control of these infections may have on the burden of epilepsy, particularly towards efforts to reduce the clinical and psychosocial burden of epilepsy.

We performed an analysis of people with epilepsy with well-defined clinical features to examine if exposure to common infections with a propensity for the central nervous system (CNS) may play a role in the early onset of epilepsy, convulsive status epilepticus, frequent seizures, abnormal electroencephalograph (EEG) findings, intellectual disabilities, neurological deficits as well as other medical comorbidities of epilepsy e.g. malnutrition. We computed the proportion of severe epilepsy that is attributable to these infections, which allows us to estimate the clinical and psychosocial burden of epilepsy that would be eliminated following the control of these infections.

Methods

Ethical considerations

The study was approved by the ethics committees or ethics review boards in each of the participating countries (Clearance number: M080455 for Agincourt, South Africa; IHI/IRB/No A 70-2009 for Ifakara, Tanzania; Reference number: HS 663 for Iganga, Uganda; SSC number 787 for Kilifi, Kenya; FW A number 00011103 for Kintampo, Ghana). All participants or guardians gave written informed consent before responding to study-related questions.

Study site and population

The study was carried out in sites in five African countries with Health Demographic Surveillance Systems (HDSS), which are part of the International Network for the Demographic Evaluation of Populations and Their Health (INDEPTH): Agincourt, South Africa; Kintampo, Ghana; Kilifi, Kenya; Ifakara, Tanzania; and Iganga-Mayuge, Uganda. These sites collect health and vital demographic data from residents on a regular cyclical basis. The study population for each HDSS was described in detail previously (Ngugi et al., 2013).

Study design

People with epilepsy were identified from a 3-stage community cross-sectional survey carried out between 2008 and 2011 (Ngugi et al., 2013). Screening for history of convulsions was conducted in stage I, followed by administration of a detailed questionnaire to describe seizures in stage II, and a neurologial assessment by a clinician to diagnose epilepsy in stage III. Formal validation of this three-stage methodology is published elsewhere (Ngugi et al., 2012), and findings supported need for continued efforts to develop and improve case-ascertainment methods in population-based epidemiological studies of epilepsy in LMIC. Community members diagnosed with epilepsy were tested for antibodies to HIV and infectious parasites (Toxocara canis, Onchocerca volvulus, Plasmodium falciparum, Toxoplasma gondii, and Taenia solium) and formed the sample for this case-comparison study. The exposure was any of the listed infections and the outcomes were the presenting features of epilepsy. All study materials can be found as extended data (Langat et al., 2021).
Sampling
The population consisted of 1,711 patients diagnosed with epilepsy in the five sites. Respondents were tested for *Toxocara canis*, *Onchocerca volvulus*, *Plasmodium falciparum*, *Toxoplasma gondii*, HIV and *Taenia solium* (exposed). HIV was tested because it is often comorbid with these parasitic infections. Sample size calculation showed this study needed 386 participants to determine the association between features of epilepsy and infections at 80% power and 95% level of confidence (supplementary appendix 1). However, we utilized all data available (997 patients) in this study.

Procedure
Clinical assessments and definitions. Most clinical and EEG features, treatment and detrimental consequences were obtained through clinical examination and EEG recordings performed by trained clinicians, and questionnaires. The clinical and neurophysiological features of epilepsy have been reported previously (Kariuki et al., 2014; Kariuki et al., 2016). Epilepsy was defined as ≥2 unprovoked seizures occurring at least 24 hours apart and was classified as active if at least one seizure occurred within the previous 12 months (Thurman et al., 2011).

Briefly, convulsive status epilepticus was defined as seizures lasting >30 minutes or intermittent seizures lasting for 30 minutes without recovery of consciousness. Seizure frequency was categorized into daily (at least one each day), weekly (at least one a week), monthly (at least one a month), and yearly (at least one a year). An EEG was categorized as abnormal if there was evidence of an abnormal background, focal changes, interictal epileptiform activity or an abnormal response to either of the activation procedures (hyperventilation or photic stimulation). Seizures were classified as focal, generalized, or other. Intellectual disability was assessed by a clinician observing young children who had problems performing the standardized test of a locally adapted developmental inventory, or by assessing an adult’s awareness of person, place and time. Malnutrition was defined as a weight-for-age z score value of −2 or lower or a mid-upper arm circumference less than 11.5 cm. Neurological deficits were defined as an inability to do things and walk or sit upright if of an appropriate age. Severe epilepsy was considered in a person with epilepsy plus focal seizures, frequent seizures, abnormal EEG, neurological deficits or intellectual disability.

Serological assay analysis. Data on assays for parasitic and HIV infections were obtained from the work by Kamuyu and colleagues (Kamuyu et al., 2014). They determined infection status through analysis of blood samples to detect antibodies to the infectious parasites and HIV. The kits and techniques used, criteria for cut-off and sensitivity and specificity have been described (Kamuyu et al., 2014). These assays were performed on 986 people with epilepsy.

Data management and statistical analysis
The data was exported from MS Excel to STATA version 15 for sampling and analysis. Data cleaning was done to assess completeness of data and exclude duplicates. For continuous data (e.g. age), histograms were plotted to show distribution. Mean (standard deviation (SD))/median (Inter-quartile range (IQR)) were reported depending on the nature of the distribution of data (i.e. whether or not the data is normally distributed). Histogram plots and Shapiro-Wilk’s test of normality were performed to check for normality of data, followed by transformation where appropriate. Categorical data such as sex, education, HIV status were illustrated using bar charts, with association frequencies and proportions presented in tables.

Student’s t-test was used to compare means of titers of infection in those with severe features of epilepsy and those without, if the raw or transformed data was normally distributed. For non-parametric continuous data, Mann-Whitney U test was used. The association between parasitic infections (predictors) and features of epilepsy (outcomes) was determined using a mixed effects modified Poisson regression model with robust standard errors. Since our outcomes are binary, using robust standard errors rectified overdispersion and produced reliable estimates. Modified Poisson regression model was chosen over log-binomial model for two reasons: (i) it is not largely affected by convergence problems, and (ii) it allows for addition of random effect(s) variable while log-binomial model does not. The model uses a log function to link a binary outcome (feature of epilepsy) to a set of predictors (infections and confounders), while accounting for clustering effect of site. To obtain crude relative risks, simple modified Poisson regression model with site as a random effect was used. Adjusted relative risks were obtained using multiple modified Poisson regression models with site as a random effect. We chose relative risk over odds ratio (OR) since the prevalence of some features was >10%, to avoid exaggerating risks with OR. Relative risks approximate prevalence ratios in cross-sectional studies, and are considered appropriate when outcomes are common and short-lived e.g. exposure to infections. In this model, the outcomes were the various clinical, or neurophysiological features of epilepsy (focal seizures, status epilepticus, frequent seizures [daily/weekly], neurological deficits, abnormal EEG, cognitive difficulties, malnutrition) and predictors were the parasitic infections most commonly associated with epilepsy (*Toxocara canis*, *Onchocerca volvulus*, *Plasmodium falciparum*, *Toxoplasma gondii*, *Taenia solium*, and HIV (included because increases risk for these parasites)) combined or considered individually together. The model was accounted for age, sex, other socioeconomic confounders and ASM use. Biological (additive) interaction was assessed to determine public health implications of co-infections on features of epilepsy. Biologic interaction is more informative than the multiplicative interaction in the sense that the former gives the additive effect (synergism/antagonism) of exposures on the feature of epilepsy, by determining the relative excess risk due to interaction (RERI). RERI enabled us to know whether the combined effect of the exposures exceeds (synergism) or is less than (antagonism) the effect of each considered individually. RERI was determined as follows:

\[
\text{Additive interaction (RERI)} = (p_{11} - p_{00}) - (p_{10} - p_{00}) + (p_{10} - p_{00}) \]  
(1)

Where;

\( p_{00} \) - Prevalence of the epileptic feature when both infections are absent; \( p_{11} \) - Prevalence of epileptic feature when both infections are present; \( p_{10} \) and \( p_{01} \) - Prevalence of epilepsy feature when one infection is present.
**Results**

**General description**
A total of 997 participants with active convulsive epilepsy from the five African sites were included in the analysis. The overall proportion of males was 51% across all the samples, ranging from 48% in Ifakara to 56% in Agincourt. The overall median (IQR) age was 20.0 years (13.0 – 32.5), being lowest in Iganga (12.0, IQR: 5.0–21.0) and highest in Agincourt (29.0, IQR:18.0–45.0). There was a significant difference in age (P=0.0001) across the sites (supplementary figure 1).

The distribution of these and other sociodemographic characteristics including education and employment status are shown in Table 1 and most characteristics varied by site.

**Antibody titres and features of epilepsy**
There was significantly higher median antibody titer levels of HIV in severe epilepsy (optical density (OD)=0.14 (IQR: 0.10-0.15)) compared to non-severe epilepsy (0.13 (IQR: 0.11-0.18)) (P<0.001). There were lower median antibody titer levels of *Onchocerca volvulus* in severe epilepsy [optical density, OD=0.09 (IQR: 0.08-0.28)] compared to non-severe epilepsy [0.10 (IQR: 0.08-0.36); P=0.038. No significant differences for antibody tires to other infections were noted between severe and non-severe epilepsy (Table 2).

More than three quarters (88%) of the study population were exposed to some infection.

**Associations of parasitic and HIV infections with features of epilepsy among all participants**
In the crude analysis, presence of infections as shown in Figure 1, was associated with convulsive status epilepticus (RR=2.79, 95% confidence interval (95%CI):2.53-3.08) and neurologic deficits (RR=1.73, 95%CI:1.35-2.22). After adjusting for age, sex, education and employment, presence of infections

### Table 1. Socio-demographic characteristics and comorbidities of study population by site.

| Characteristic                  | Agincourt (n=176) | Ifakara (n=287) | Iganga (n=84) | Kilifi (n=276) | Kintampo (n=174) | Total (n=997) |
|--------------------------------|-------------------|-----------------|---------------|---------------|------------------|---------------|
| **Socio-demographics**         |                   |                 |               |               |                  |               |
| Median age in years (IQR)      | 29.0 (18.0–45.0)  | 18.3 (12.0–30.9) | 12.0 (5.0–21.0) | 18.0 (11.0–27.5) | 21.0 (15.0–29.0) | 20.0 (13.0–32.5) |
| Median age (years) at onset of seizures (IQR) | 13.7 (2.6–31.1) | 8.9 (2.0–16.5) | 2.1 (0.5–7.9) | 3.3 (1.0–13.4) | 9.8 (3.0–16.8) | 6.7 (1.6–16.8) |
| Sex; n (%)                     |                   |                 |               |               |                  |               |
| Female                         | 78(44.3)          | 150(52.3)       | 40(47.6)      | 143(51.8)     | 78(44.8)         | 489(49.0)     |
| Male                           | 98(55.7)          | 137(47.7)       | 44(52.4)      | 133(48.2)     | 96(55.2)         | 508(51.0)     |
| Education (age≥5); n (%)       |                   |                 |               |               |                  |               |
| Schooled                       | 121(71.6)         | 160(58.6)       | 43(63.2)      | 153(60.5)     | 107(62.6)        | 584(62.6)     |
| Unschooled                     | 48(28.4)          | 113(41.4)       | 25(36.8)      | 100(39.5)     | 64(37.4)         | 350(37.5)     |
| Employment (age≥18); n (%)     |                   |                 |               |               |                  |               |
| Employed                       | 7(5.3)            | 106(72.6)       | 4(16.7)       | 42(30.9)      | 54(47.8)         | 213(38.6)     |
| Unemployed                     | 126(94.7)         | 40(27.4)        | 20(83.3)      | 94(69.1)      | 59(52.2)         | 339(61.4)     |
| **Co-morbidities**             |                   |                 |               |               |                  |               |
| Neurologic deficits; n (%)     | No 139(79.9)      | 263(92.3)       | 71(84.5)      | 231(83.7)     | 143(88.3)        | 847(86.3)     |
|                                | Yes 35(20.1)      | 22(7.7)         | 13(15.5)      | 45(16.3)      | 19(11.7)         | 134(13.7)     |
| Cognitive impairment; n (%)    | No None           | 185(86.1)       | 67(87.0)      | 212(82.5)     | 141(83.9)        | 605(84.4)     |
|                                | Yes None          | 30(13.9)        | 10(13)        | 45(17.5)      | 27(16.1)         | 112(15.6)     |
| Malnutrition; n (%)            | No 157(89.2)      | 252(87.8)       | 64(77.1)      | 232(84.1)     | 150(86.2)        | 855(85.8)     |
|                                | Yes 19(10.8)      | 35(12.2)        | 19(22.9)      | 44(15.9)      | 24(13.8)         | 141(14.2)     |

IQR=interquartile range
Table 2. Association between infection status and clinical and comorbidity features of epilepsy (pooled data).

| Feature                      | Infection status | Crude Relative Risk (C.I) | P-value | Adjusted Relative Risk (C.I) | P-value |
|------------------------------|------------------|---------------------------|---------|-----------------------------|---------|
|                              | Uninfected n (%) | Infected n (%)            |         |                             |         |
| Focal seizures               | No               | 64(11.7)                  | 1.08    | (0.95-1.22)                 | 0.247   | 0.97 (0.73-1.30) | 0.873 |
|                              | Yes              | 52(11.6)                  | 1.10    | (0.95-1.25)                 | 0.877   | 0.97 (0.73-1.30) | 0.873 |
| Abnormal EEG                 | No               | 41(12.5)                  | 1.00    | (0.90-1.11)                 | 0.996   | 0.96 (0.83-1.11) | 0.588 |
|                              | Yes              | 49(12.5)                  | 1.00    | (0.90-1.11)                 | 0.996   | 0.96 (0.83-1.11) | 0.588 |
| Status epilepticus           | No               | 111(13.2)                 | 2.79    | (2.53-3.08)                 | <0.001  | 0.90 (0.32-2.54) | 0.845 |
|                              | Yes              | 5(3.3)                    | 1.39    | (0.99-1.94)                 | 0.059   | 0.25 (0.11-0.57) | 0.001 |
| Frequency of seizures        | Monthly          | 46(10.2)                  | 1.14    | (0.56-2.31)                 | 0.722   | 2.85 (1.95-4.16) | <0.001 |
|                              | Daily/weekly     | 15(7.3)                   | 1.40    | (0.52-3.80)                 | 0.509   |                   |       |
| Cognitive/learning difficulties| No               | 31(5.1)                   | 1.39    | (0.99-1.94)                 | 0.059   | 0.25 (0.11-0.57) | 0.001 |
|                              | Yes              | 4(3.6)                    | 3.62    | (1.35-10.22)                | <0.001  | 1.40 (0.52-3.80) | 0.509 |
| Neurologic deficits          | No               | 102(12.0)                 | 1.73    | (1.35-2.22)                 | <0.001  | 1.40 (0.52-3.80) | 0.509 |
|                              | Yes              | 13(9.7)                   | 1.40    | (1.00-2.00)                 | 0.258   | 0.91 (0.48-1.73) | 0.772 |
| Malnutrition                 | Not malnourished | 95(11.1)                  | 0.69    | (0.43-0.98)                 | <0.001  | 1.40 (0.52-3.80) | 0.509 |
|                              | Malnourished     | 21(14.9)                  | 1.39    | (0.99-1.94)                 | 0.059   | 0.25 (0.11-0.57) | 0.001 |

CI=confidence intervals; EEG=electroencephalograph

was associated with higher frequency (daily/weekly) of seizures (RR=2.85, 95%CI:1.95-4.16), and adjusting for these variables appeared to reduce risk for intellectual disability (RR=0.25, 95%CI:0.11-0.57) (Figure 1). More detailed results also shown in Table 2.

In the sensitivity analysis of individual infections, exposure to falciparum malaria increased the risk of status epilepticus (RR=1.79, 95%CI:1.19-2.69), but reduced risk for several other features (Table 3). HIV increased risk for seizure frequency (RR=1.16, 95%CI:1.07-1.27) and abnormal EEG (RR=1.30, 95%CI:1.01-1.69) among others. *O. volvulus* increased risk for convulsive status epilepticus (RR=2.32, 95%CI:1.35-3.98), *T. solium* for abnormal EEG (RR=1.54, 95%CI:1.31-1.82) and *T. canis* for neurological deficits (RR=1.69, 95%CI:1.53-1.85). Other associations are in Table 3.

Associations of parasitic/HIV infections with features of epilepsy among children

In the crude analysis, exposure to parasitic/HIV infections was associated with convulsive status epilepticus (RR=4.50, 95%CI:3.89-5.19), intellectual disability (RR=1.59, 95%CI:1.20-2.11) and malnutrition (RR=1.40, 95%CI:1.00-1.90) having controlled for age, sex and other infections (Table 5). Exposure to *T. gondii* was protective for neurological deficits (RR=0.57, 95%CI:0.43-0.75) having controlled for age, sex and other infections (Table 5).
Figure 1. Associations between infections and epilepsy features in the study population (pooled). Note: For avoidance of doubt, the features displayed in the plot are outcomes (dependent variables). The main predictor is parasitic/HIV infections (having any of these), adjusted for socio-demographics. Therefore, the effect size (relative risk (RR)) represents the effect of infections on a given feature, and not the other way round. EEG=electroencephalograph; CI=confidence interval.

Associations of infections with features of epilepsy among adults
Only neurological deficits (RR=1.76, 95%CI:1.17-2.65) was associated with presence of any infections in bivariate analysis. After adjusting for age, sex, education and employment, frequent seizures (RR=2.58, 95%CI:1.71-3.89) and cognitive difficulties (RR=0.23, 95%CI:0.11-0.47) were significantly associated with presence of infections (Figure 3). More detailed results are shown in Table 6.

In the sensitivity analysis for individual infections, exposure to *P. falciparum* infection was significantly associated with convulsive status epilepticus (RR=1.74, 95%CI: 1.05-2.90) and frequent seizures (RR=3.07, 95%CI: 2.14-4.42), adjusting for age, sex, education and employment status. Additionally, after controlling for the confounders, infection with *O. volvulus* was significantly associated with status epilepticus (RR=2.31, 95%CI:1.36-3.93) and focal seizures (RR=0.80, 95%CI: 0.71-0.91). Further, infection with *T. solium* was significantly associated with malnutrition (RR=1.53, 95%CI:1.11-2.10) in the adjusted analysis (Table 7).

Interaction between infections and features of epilepsy
In the analysis for multiplicative interactions, several paired infections showed interactions (Table 8 and supplementary table 1). In particular, *P. falciparum* and HIV interacted to increase the risk for convulsive status epilepticus (RR=2.35, 95%CI:1.38-4.00) and frequent seizures (RR=4.14, 95%CI:3.04-5.65), but the interaction reduced the risk for cognitive impairment (RR=0.32, 95%CI: 0.24-0.44). Similarly, HIV interacted with *O. volvulus* to increase the risk for convulsive status epilepticus (RR=4.46, 95%CI:2.05-9.71), but reduced the risk for frequent seizures (RR=0.74, 95%CI:0.63-0.88).

In the analysis for biological interactions, *T. gondii* and *T. canis* interacted synergistically to increase the risk of
| Epilepsy features (outcomes) | Infections (predictors) | P. falciparum (+ve vs -ve) (ref: -ve) | HIV (+ve vs -ve) (ref: -ve) | T. Gondii (+ve vs -ve) (ref: -ve) | O. Volvulus (+ve vs -ve) (ref: -ve) | T. solium (+ve vs -ve) (ref: -ve) | T. canis (+ve vs -ve) (ref: -ve) | RR (C.I) | P-value | RR (C.I) | P-value | RR (C.I) | P-value | RR (C.I) | P-value | RR (C.I) | P-value | RR (C.I) | P-value |
|-----------------------------|-------------------------|--------------------------------------|-----------------------------|-----------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|--------|---------|--------|---------|--------|---------|--------|---------|---------|--------|---------|---------|
| Focal seizure               |                         |                                      |                              |                                   |                                   |                                   |                                   | 0.33   | 0.28–0.37 | 0.33   | <0.001  | 1.14   | 1.02–1.26 | 0.017   | 1.05   | 0.81–1.37 | 0.691  | 0.81   | 0.71–0.93 | 0.003  | 0.57   | 0.07–4.72 | 0.606  | 0.81   | 0.56–1.17 | 0.263  |
| Status epilepticus          |                         |                                      |                              |                                   |                                   |                                   |                                   | 1.79   | 1.19–2.69 | 0.005  | 0.05    | 1.88   | 1.21–2.93 | 0.005   | 0.71   | 0.64–0.80 | <0.001 | 2.32   | 1.35–3.98 | 0.002  | 0.83   | 0.24–2.80 | 0.759  | 1.28   | 0.29–5.56 | 0.743  |
| Frequent seizures           |                         |                                      |                              |                                   |                                   |                                   |                                   | 0.85   | 0.55–1.31 | 0.459  | 0.05    | 1.16   | 1.07–1.27 | 0.007   | 1.01   | 0.75–1.37 | 0.950  | 0.76   | 0.68–0.84 | <0.001 | 0.47   | 0.10–2.28 | 0.0347 | 1.27   | 1.02–1.56 | 0.030  |
| Cognitive difficulties      |                         |                                      |                              |                                   |                                   |                                   |                                   | 0.23   | 0.21–0.26 | 0.001  | 0.01    | 0.71   | 0.58–0.88 | 0.001   | 1.01   | 0.74–1.36 | 0.967  | 1.06   | 0.82–1.38 | 0.640  | 0.55   | 0.15–2.04 | 0.374  | 1.16   | 0.67–2.00 | 0.603  |
| Neurologic deficits         |                         |                                      |                              |                                   |                                   |                                   |                                   | 0.61   | 0.46–0.82 | 0.001  | 0.01    | 0.59   | 0.28–1.26 | 0.174   | 0.79   | 0.47–1.33 | 0.379  | 0.79   | 0.32–1.98 | 0.613  | 0.76   | 0.26–2.24 | 0.619  | 1.69   | 1.53–1.85 | <0.001 | 0.96   | 0.84–1.09 | 0.517  |
| Abnormal EEG                |                         |                                      |                              |                                   |                                   |                                   |                                   | 0.83   | 0.69–0.99 | 0.041  | 0.04    | 1.30   | 1.01–1.69 | 0.041   | 1.19   | 0.94–1.51 | 0.150  | 0.93   | 0.69–1.26 | 0.639  | 1.54   | 1.31–1.82 | <0.001 | 0.96   | 0.84–1.09 | 0.517  |
| Malnutrition                |                         |                                      |                              |                                   |                                   |                                   |                                   | 0.79   | 0.66–0.93 | 0.006  | 0.00    | 1.33   | 0.39–4.56 | 0.652   | 0.84   | 0.62–1.14 | 0.258  | 0.94   | 0.73–1.21 | 0.654  | 1.97   | 1.18–3.27 | 0.009  | 1.12   | 0.86–1.47 | 0.396  |

Note: Frequent seizures – having seizures on a daily/weekly basis. EEG=electroencephalograph; RR=risk ratio; CI=confidence intervals.
Figure 2: Associations between infections and epilepsy features in children (<18 years). Note: For avoidance of doubt, the features displayed in the plot are outcomes (dependent variables). The main predictor is parasitic/HIV infections (having any of these), adjusted for socio-demographics. Therefore, the effect size (relative risk (RR)) represents the effect of infections on a given feature, and not the other way round. EEG=electroencephalograph; CI=confidence interval.

### Features of epilepsy (outcomes) vs. Effect of having at least one infection (Ref: having none)

| Features of epilepsy (outcomes) | Crude associations | Adjusted associations |
|---------------------------------|--------------------|----------------------|
| RR (95% CI)                     | RR (95% CI)        |
| Focal seizures                  | 1.19 (0.94, 1.51)  | 1.14 (0.88, 1.48)    |
| Abnormal EEG                    | 1.11 (0.88, 1.40)  | 1.19 (1.05, 1.35)    |
| Status epilepticus              | 4.50 (3.89, 5.19)  | 4.68 (3.79, 5.78)    |
| Frequent seizures               | 1.05 (0.75, 1.47)  | 1.09 (0.67, 1.77)    |
| Cognitive difficulties           | 2.10 (1.41, 3.12)  | 2.13 (1.35, 3.34)    |
| Neurologic deficits             | 1.49 (1.10, 2.05)  | 1.92 (1.42, 2.61)    |
| Malnutrition                    | 0.69 (0.59, 0.80)  | 0.93 (0.80, 1.09)    |

Convulsive status epilepticus (RERI = 0.92, 95%CI:0.46-1.38) while *P. falciparum* interacted with HIV to reduce the risk of convulsive status epilepticus (RERI = -4.02, 95%CI:-7.95 - -0.08) (Table 9). Detailed results for biological interactions are shown in supplementary table 2, while those for population attributable fractions are in supplementary table 3.

### Discussion

This study provides important evidence that parasitic infections that have a propensity for the CNS are not only associated with epilepsy, but also determine the occurrence of features and phenotypes of epilepsy. In children with epilepsy, exposure to infections is particularly associated with convulsive status epilepticus, neurological deficits and intellectual disability, while in adults it is associated with frequent seizures. Individual infections may increase some features (e.g. falciparum malaria increasing risk for convulsive status epilepticus) but not others. These infections may interact synergistically or antagonistically to affect the features of epilepsy, and their prevention may reduce up to 26% severe epilepsy.

**Antibody titres and prevalence for parasitic/HIV infections**

There was significant difference in median antibody titer levels between severe and non-severe epilepsy only for HIV (P<0.001) and *Onchocerca volvulus* (P=0.038), suggesting that these levels are ubiquitous representation of exposure, and reliable associations should be measured from cut-offs derived from high antibody titres. Using predefined cut-offs, infections were more prevalent across all features considered, indicating that these infections could be potential risk factors for development of these epilepsy features. The
Table 4. Association between infection status and clinical and comorbid features of epilepsy in children (< 18 years).

| Feature                        | Infection status | Crude Relative Risk (C.I) | P-value | Adjusted Relative Risk (C.I) | P-value |
|--------------------------------|------------------|---------------------------|---------|-----------------------------|---------|
|                                | Uninfected n (%) | Infected n (%)            |         |                             |         |
| Focal seizures                 | No               | 34(14.2)                  | 1.19    | (0.94-1.51)                 | 0.155   |
|                                | Yes              | 26(14.2)                  |         |                             |         |
| Abnormal EEG                   | No               | 19(16.7)                  | 1.11    | (0.88-1.40)                 | 0.366   |
|                                | Yes              | 23(13.5)                  |         |                             |         |
| Status epilepticus             | No               | 56(16.8)                  | 4.50    | (3.89-5.19)                 | <0.001  |
|                                | Yes              | 4(4.6)                    |         |                             |         |
| Frequency of seizures          | Monthly          | 15(9.3)                   | 1.05    | (0.75-1.47)                 | 0.783   |
|                                | Daily/weekly     | 10(9.7)                   |         |                             |         |
| Cognitive/learning difficulties | No               | 27(9.6)                   | 2.10    | (1.41-3.12)                 | <0.001  |
|                                | Yes              | 2(4.4)                    |         |                             |         |
| Neurologic deficits            | No               | 54(14.6)                  | 1.49    | (1.10-2.05)                 | 0.011   |
|                                | Yes              | 5(10.2)                   |         |                             |         |
| Malnutrition                   | Not malnourished | 47(13.0)                  | 0.69    | (0.59-0.80)                 | <0.001  |
|                                | Malnourished     | 13(21.3)                  |         |                             |         |

EEG=electroencephalograph; C.I=confidence intervals

prevalence of infections were significantly greater than in the general population since they are based on an epilepsy cohort, whose exposure to infections is already known to be relatively greater (Carter et al., 2004).

Associations between any parasitic/HIV infections and features of epilepsy in all populations

Among all the study population, exposure to any of the infections were associated with increased risk of having frequent (daily/weekly) seizures and an increased risk of cognitive difficulties, after controlling for confounding effects, including the use of ASM. HIV-positive individuals have increased risk of abnormal EEG, which has been noted in previous studies (Kellinghaus et al., 2008). T. canis was associated with neurological deficits which is not surprising since neurological involvement has been reported (Finsterer & Auer, 2007). Associations that appeared protective were observed especially for some specific infections. This may be due to absence of these features and phenotypes when samples for positive assays were collected or may be a spurious association. Since susceptibility to infections and pathogenesis of epilepsy following these infections is different between children and adults, it warranted evaluations of these associations between two population strata i.e. adults and children/minors separately.

Associations between any parasitic/HIV infections and features of epilepsy in children

Among children with epilepsy, we found that exposure to infections was associated with higher risk of having status epilepticus, intellectual disabilities and neurologic deficits after adjusting for age and sex. Analysis of individual infections showed that P. falciparum increased the risk for convulsive status epilepticus, and T. canis that for neurological deficits, while interaction of several infections may explain the intellectual disability.

Children have low immunity to infections and also have a developing brain, and it is not surprising that infections
Table 5. Adjusted associations of infections and features of epilepsy among minors (<18 years).

| Infections (predictors) | P. falciparum (+ve vs –ve) (ref: -ve) | HIV (+ve vs –ve) (ref: -ve) | T. Gondii (+ve vs –ve) (ref: -ve) | O. Volvulus (+ve vs –ve) (ref: -ve) | T. solium (+ve vs –ve) (ref: -ve) | T. canis (+ve vs –ve) (ref: -ve) |
|-------------------------|--------------------------------------|-----------------------------|-----------------------------------|-----------------------------------|-----------------------------------|----------------------------------|
| RR (C.I)                | P-value                              | RR (C.I)                    | P-value                           | RR (C.I)                          | P-value                           | RR (C.I)                         |
| Focal seizure           | 0.90 (0.68-1.21)                     | 0.64 (0.19-2.13)            | 0.467 (0.00-0.75)                 | 0.75 (0.68-0.82)                  | <0.001                            | 0.90 (0.37-2.24)                 |
| Status epilepticus      | 2.26 (1.85-2.76)                     | <0.001                      | 0.44 (0.03-5.96)                  | 0.51 (0.14-1.80)                  | 0.327 (0.18-0.75)                 | 0.006 No convergence             |
| Frequent seizures       | 0.80 (0.42-1.53)                     | 0.506 (0.10-1.08)           | 0.019 (0.00-0.75)                 | 1.48 (1.07-2.06)                  | 0.933 (0.52-1.58)                 | 0.742 No convergence             |
| Cognitive difficulties   | 0.15 (0.13-0.17)                     | <0.001                      | 0.32 (0.10-1.08)                  | 0.066 (0.00-0.75)                 | 0.275 (0.55-4.29)                 | 0.409                            |
| Neurologic deficits     | 0.47 (0.33-0.68)                     | <0.001                      | 0.41 (0.07-2.31)                  | 0.314 (0.43-0.75)                 | <0.001                            | 1.54 (0.55-4.29)                 |
| Abnormal EEG            | 0.61 (0.46-0.81)                     | 0.001                       | 1.14 (1.02-1.28)                  | 0.019 (0.18-1.57)                 | 0.377 (0.59-1.95)                 | 0.826                            |
| Malnutrition            | 1.43 (1.01-2.04)                     | 0.046                       | 1.99 (0.86-4.58)                  | 0.106 (0.45-1.34)                 | 0.038 (0.45-1.34)                 | 5.20 (0.98-27.7)                 |

Note: No convergence – the model would not produce parameter estimates due to inadequate cell frequencies; Frequent seizures – having seizures on a daily/weekly basis. EEG=electroencephalograph; RR=relative risk; C.I=confidence intervals.
determined three features of epilepsy that are pathognomonic of severe childhood seizure disorders. Convulsive status epilepticus is common in children and previous studies showed that malaria is the most important cause (Sadarangani et al., 2008). Kariuki et al. in 2011 hypothesized that the non-malarial status epilepticus that did not decline over a period of malaria reduction was probably caused by epilepsy (Kariuki et al., 2011). It has been established in a recent multisite study that status epilepticus occurs in over 25% of people with epilepsy (Kariuki et al., 2015), and infections may contribute to this excess burden of prolonged seizures.

Associations between any parasitic/HIV infections and features of epilepsy in adults

Among adults with epilepsy, exposure to any infection was associated with increased risk for frequent seizures, but reduced risk for intellectual disability. Analysis of individual impairments shows that the increased risk for frequent seizures, status epilepticus was determined by falciparum malaria, which appeared to reduce the risk for intellectual disability in adults, perhaps suggesting these are related to other causes. Status epilepticus was also increased following *O. volvulus*, with other infections showing protection against some of these features.

The positive association of infections with frequent seizures is expected, since we have demonstrated in children that repetitive seizures are highly attributable to malaria (Kariuki et al., 2011). Presence of any infections were protective for intellectual disability in adults with epilepsy perhaps because of absence or low frequency of infections in this group of people movement of adults with cognitive difficulties is restricted indoors, resulting in less exposure to infections. Alternatively, it may be due to reporting bias whereby adults with epilepsy conceal their cognitive impairments, which is easily recognized as a condition for children (Carter et al., 2005) or due to counselling out of effect sizes of infections that confers susceptibility by those that reduces risk.
Association of individual parasitic/HIV infections with features of epilepsy

When we probed the effects of individual infections on the features of epilepsy, *P. falciparum* was protective for most epilepsy features, except for status epilepticus. The same case applied to children, but in adults, *P. falciparum* infection was associated with increased risk of both status epilepticus and daily/weekly seizures. This finding agrees with that of another study done in Africa, where infection with falciparum malaria were important risk factors for status epilepticus (Kariuki et al., 2015). We also found that exposure to falciparum malaria appeared as protective for focal seizures and frequent seizures in our study, supporting the previous association between *P. falciparum* and malnutrition in general hospital admissions (Gone et al., 2017), but other factors involved in this association should be considered. HIV was a risk factor for frequent daily/weekly seizures, and abnormal EEG, suggesting it has neurological involvement. Seizures have been reported in HIV with or without epilepsy (Kellinghaus et al., 2008); frequent seizures in our study are likely due to epileptogenic nature of HIV since its negative association with neurological deficits appears to rule out contribution by brain damage. *O. volvulus* was protective for focal seizures and frequent seizures but increased the risk for status epilepticus. *O. volvulus* likely has diffuse brain involvement resulting in convulsive status epilepticus with a generalized onset in the brain, thus the negative association with focal seizures. *Taenia solium* increased the risk of having abnormal EEG but reduced the risk of early onset seizures. The finding that *T. solium* appeared to reduce the risk of early onset seizures may be because it is more common in adult onset epilepsy (Ngugi et al., 2013).

Interaction of parasitic/HIV infections and features of epilepsy

More interactions were noted in the additive scale than in the multiplicative scale, but the later would only be helpful in examining the contribution of a risk factor to a disease. Interaction on the additive scale has public health importance in that it is easier to quantify the frequency of a disease that would be controlled by the removal of risk factors. The many significant combinations of interaction in the multiplicative scale suggests that multiple infections determine the features and phenotypes of epilepsy in Africa. Interaction tests performed on additive scale revealed that infections interact either synergistically or antagonistically in influencing the features of epilepsy. For instance, *Toxoplasma gondii* and *Toxocara canis* interacted synergistically to increase the risk of status epilepticus, implying that the number of status epilepticus cases due to the coinfection is higher than the total number of cases contributed by the two infections separately. In contrast, *P. falciparum* and HIV interacted antagonistically towards status epilepticus, implying that co-infections worsen the prognosis of epilepsy, and can also be found in those with milder features. These interaction findings support

### Table 6. Association between infection status and clinical and comorbid features of epilepsy in adults (≥18 years).

| Feature                  | Infection status | Uninfected n (%) | Infected n (%) | Crude Relative Risk (C.I) | P-value | Adjusted Relative Risk (C.I) | P-value |
|--------------------------|------------------|------------------|---------------|--------------------------|---------|-----------------------------|---------|
| Focal seizures           | No               | 30(9.8)          | 26(9.7)       | 0.94 (0.81-1.09)         | 0.399   | 0.99 (0.81-1.21)            | 0.911   |
|                          | Yes              | 277(90.2)        | 241(90.3)     |                          |         |                             |         |
| Abnormal EEG             | No               | 22(10.3)         | 26(11.8)      | 0.93 (0.81-1.07)         | 0.301   | 0.97 (0.83-1.14)            | 0.739   |
|                          | Yes              | 191(89.7)        | 194(88.2)     |                          |         |                             |         |
| Status epilepticus       | No               | 55(10.8)         | 1(1.5)        | 1.19 (0.62-2.26)         | 0.600   | 0.89 (0.33-2.40)            | 0.814   |
|                          | Yes              | 455(89.2)        | 64(98.5)      |                          |         |                             |         |
| Frequency of seizures    | Monthly          | 31(10.7)         | 5(4.9)        | 1.77 (0.85-3.71)         | 0.127   | 2.58 (1.71-3.89)            | <0.001  |
|                          | Daily/weekly     |                 |               |                          |         |                             |         |
| Cognitive/learning difficulties | No          | 4(1.2)          | 2(3.0)        | 0.51 (0.13-1.93)         | 0.322   | 0.23 (0.11-0.47)            | <0.001  |
|                          | Yes              | 320(98.8)        | 65(97.1)      |                          |         |                             |         |
| Neurologic deficits      | No               | 48 (10.1)        | 8 (9.4)       | 1.76 (1.17-2.65)         | 0.006   | 1.46 (0.59-3.65)            | 0.414   |
|                          | Yes              | 429(89.9)        | 77(90.6)      |                          |         |                             |         |
| Malnutrition             | Not malnourished | 48 (9.7)         | 8 (10)        | 0.83 (0.51-1.34)         | 0.437   | 0.89 (0.48-1.66)            | 0.716   |
|                          | Malnourished     | 446(90.3)        | 72(90)        |                          |         |                             |         |

EEG=electroencephalograph; C.I=confidence intervals
| Epilepsy features (outcomes) | Infections (predictors) |  |  |  |  |  |  |  |  |  |
|-----------------------------|-------------------------|---|---|---|---|---|---|---|---|---|
|                             | *P. falciparum* (+ve vs -ve) | *HIV* (+ve vs -ve) | *T. Gondii* (+ve vs -ve) | *O. Volvulus* (+ve vs -ve) | *T. solium* (+ve vs -ve) | *T. canis* (+ve vs -ve) |
|                             | (ref: -ve) | (ref: -ve) | (ref: -ve) | (ref: -ve) | (ref: -ve) | (ref: -ve) |
|                             | RR (C.I) | P-value | RR (C.I) | P-value | RR (C.I) | P-value | RR (C.I) | P-value | RR (C.I) | P-value |
| Focal seizures              | 1.13     | 0.96–1.34 | 0.015 | 1.05 | 0.81–1.35 | 0.719 | 0.80 | 0.71–0.91 | 0.001 | 0.57 | 0.07–4.71 | 0.600 | 0.81 | 0.57–1.17 | 0.269 |
| Status epilepticus          | 1.74     | 1.05–2.90 | 0.033 | 1.88 | 1.22–2.91 | 0.05 | 0.71 | 0.64–0.80 | <0.001 | 2.31 | 1.36–3.93 | 0.002 | 0.83 | 0.25–2.81 | 0.768 | 1.28 | 0.28–5.89 | 0.749 |
| Frequent seizures           | 3.07     | 2.14–4.42 | <0.001 | 0.84 | 0.68–1.04 | 0.110 | 1.02 | 0.77–1.35 | 0.893 | 0.63 | 0.39–1.01 | 0.055 | 1.38 | 0.15–12.6 | 0.778 | 0.90 | 0.64–1.28 | 0.566 |
| Cognitive difficulties       | 0.42     | 0.26–0.70 | 0.001 | 0.81 | 0.66–1.00 | 0.050 | 1.02 | 0.69–1.51 | 0.927 | 0.96 | 0.73–1.25 | 0.750 | No convergence | 1.19 | 0.77–1.83 | 0.443 |
| Neurologic deficits         | 1.15     | 0.59–2.24 | 0.685 | 0.68 | 0.55–0.86 | 0.001 | 0.84 | 0.40–1.76 | 0.644 | 0.77 | 0.29–2.04 | 0.603 | No convergence | 1.18 | 0.77–1.81 | 0.441 |
| Abnormal EEG                 | 0.97     | 0.78–1.21 | 0.772 | 1.46 | 0.93–2.30 | 0.102 | 1.17 | 0.80–1.70 | 0.418 | 0.83 | 0.73–0.95 | 0.0005 | 0.90 | 0.52–1.56 | 0.719 | 1.25 | 1.02–1.54 | 0.035 |
| Malnutrition                 | 0.68     | 0.56–0.82 | <0.001 | 1.07 | 0.43–2.66 | 0.883 | 1.09 | 0.63–1.89 | 0.763 | 0.96 | 0.66–1.41 | 0.835 | 1.53 | 1.11–2.10 | 0.009 | 1.19 | 0.86–1.64 | 0.300 |

Note: No convergence – the model would not produce parameter estimates due to inadequate cell frequencies; Frequent seizures – having seizures on a daily/weekly basis. EEG=electroencephalograph; RR=relative risk; C.I=confidence intervals
the need to screen for multiple infections in people with epilepsy.

Strengths and limitations
Strengths: This study had more than the minimum required sample size, meaning the study had enough power to answer our research questions. Also, being a multisite design, the findings can be generalized across ecological zones considered. Additionally, the mixed effects model used in this study took accounted for the correlations (homogeneity) within sites and heterogeneity across sites. Limitations: We only studied active convulsive epilepsy. The infections were assayed for exposure and not really a measure of impact of severe disease on epilepsy, which would be done with longitudinal cohort studies. Another cause of concern was the possibility of recall bias since participants were interviewed for some epilepsy features and the inherent challenge of inferring direction of causality for cross-sectional studies. Cross-sectional studies, however, are easy and inexpensive, and may be very useful in generation of new or important hypothesis for understanding pathophysiology or prognosis of health conditions if these are not previously studied or fully understood. Unmeasured risk factors could contribute to the association between infections and epilepsy features i.e. residual confounding. Some of those who agreed to participate in the follow-up evaluations may have had severe forms of epilepsy than those who dropped out,
introducing severity bias which can affect the associations. Some participants who did not participate may have been unwell or even died, which can introduce survival bias.

**Conclusions**

Features and phenotypes of epilepsy in Africa may be determined by infections and the direction of association depends on the type, frequency of infection and their interaction. Exposure to parasitic infections determine different types of features and phenotypes for children and adults, with status epilepticus and cognition being important in children and frequent seizures in adults. Taken together these findings suggests that not only are infections associated with epilepsy, they also determine the presentation of epilepsy in terms of features and phenotypes. Control of infections may reduce the risk of epilepsy becoming severe in addition to preventing epilepsy directly caused by infections in the community. Findings from this cross-sectional study are likely to inform set up of cohort studies to explore differential progression of epilepsy following exposure to infections, and to inform mass prophylaxis against exposure to infections among people already living with epilepsy.

**Previous publications**

Part of this data was published in *PLoS Negl Trop Dis* ([https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4038481/](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4038481/)) and in *Lancet Neurol* ([https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3581814/](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3581814/)) as case-control studies to examine exposure to infections as risk factors for developing epilepsy. However, none of these two articles explored the role of exposure to infections in the occurrence of features, outcomes and phenotypes among people with epilepsy, which is now presented in this paper. More details on justification for the current analysis is provided in the introduction section of the paper.

**Data availability**

**Underlying data**

Harvard Dataverse: Infections and Epilepsy. [https://doi.org/10.7910/DVN/WQZBUX (Langat et al., 2021)](https://doi.org/10.7910/DVN/WQZBUX).

This project contains the following underling data:

(i) epilepsydata_deidentified_ID.tab (used for calculating the association of exposure to infections with epilepsy features and phenotypes)

For ethical considerations and to comply with the language in the informed consent forms, the access to the dataset is controlled for general research use. Please request to access the data by completing the forms in the provided link to the data, following which permissions will be granted using procedures governed by the Data Governance Committee (DGC) of the Centre for Geographic Medicine Research Coast, Kenya Medical Research Institute. Data will be made available with the approval of the KEMRI Wellcome Trust Research Programme Data Governance Committee, only where anonymization can be adequately achieved to protect the privacy and confidentiality of the participants/respondents and any mentioned individuals and institutions, and where the proposed use is seen as relevant to the nature of the data. Where the DGC recommend this, the national KEMRI Science and Ethics Review Unit may also be asked to approve the proposed use. Conditions for data sharing are outlined in a KWTRP Data Sharing Agreement, including that the requestor shall use the data only for the agreed purpose as stipulated in the application form; shall agree to keep the data strictly confidential and shall not in any way attempt to seek to discover the identity of data subjects, to compromise or infringe on their privacy and confidentiality of their information.

**Extended data**

Harvard Dataverse: Infections and Epilepsy. [https://doi.org/10.7910/DVN/WQZBUX (Langat et al., 2021)](https://doi.org/10.7910/DVN/WQZBUX).

This project contains the following extended data:

(i) Infections and Epilepsy_Codebook.xlsx (description of variables codes and labels)

(ii) Infections Epilepsy Data Readme File.txt (brief description of the study aim and processes)

(iii) Infections and Epilepsy.do (SATA v15 analysis script)

(iv) StageIII SEEDS-Clinical Examination.doc (clinical examination form)

(v) StageIII SEEDS-Clinical History (Twi).doc (clinical history form)

(vi) StageIII SEEDS-EEG.doc (EEG interpretation form)

(vii) StageIII SEEDS-Socio-Demography Above 18(Twi).doc (adults’ sociodemographic and medical history form)

(viii) StageIII SEEDS-Socio-Demography Under 18(Twi).doc (children’s sociodemographic and medical history form)

(ix) Supplementary materials_19July2021.docx (supplementary appendix, figure and tables).

Data are available under the terms of the Creative Commons Attribution 4.0 International license (CC-BY 4.0).
References

Carter JA, Mung’ala-Odera V, Neville BGR, et al.: Persistent neurocognitive impairments associated with severe falciparum malaria in Kenyan children. J Neurol Neurosurg Psychiatry. 2005; 76(4): 476–481. PubMed Abstract | Publisher Full Text | Free Full Text

Carter JA, Neville BGR, White S, et al.: Increased prevalence of epilepsy associated with severe falciparum malaria in children. Epilepsia. 2004; 45(8): 978–981. PubMed Abstract | Publisher Full Text

Fiest KM, Sauro KM, Wiebe S, et al.: Prevalence and incidence of epilepsy: A systematic review and meta-analysis of international studies. Neurology. 2017; 88(3): 296–303. PubMed Abstract | Publisher Full Text | Free Full Text

Finsterer J, Auer H: Neurotoxocarosis. Rev Inst Med Trop Sao Paulo. 2007; 49(5): 279–87. PubMed Abstract | Publisher Full Text

Gone T, Lemango F, Elisa E, et al.: The association between malaria and malnutrition among under-five children in Shashogo District, Southern Ethiopia: a case-control study. PLoS Negl Trop Dis. 2014; 8(1): 76–85. PubMed Abstract | Publisher Full Text | Free Full Text

Kariuki SM, White S, Chengo E, et al.: Electroencephalographic features of convulsive epilepsy in Africa: A multicentre study of prevalence, pattern and associated factors. Clin Neurophysiol. 2016; 127(2): 1099–1107. PubMed Abstract | Publisher Full Text | Free Full Text

Kellinghaus C, Engbring C, Kovac S, et al.: Frequency of seizures and epilepsy in neurological HIV-infected patients. Seizure. 2008; 17(1): 27–33. PubMed Abstract | Publisher Full Text

Langat NK, et al.: Harvard dataverse: replication data for: Exposure to parasitic infections determines features and phenotypes of active convulsive epilepsy in Africa. ed.^eds. 2021; 3.

Mbuba CK, Ngugi AK, Fegan G, et al.: Risk factors associated with the epilepsy treatment gap in Kilifi, Kenya: a cross-sectional study. Lancet Neurol. 2012; 11(6): 688–696. PubMed Abstract | Publisher Full Text | Free Full Text

Ngugi AK, Bottomley C, Chengo E, et al.: The validation of a three-stage screening methodology for detecting active convulsive epilepsy in population-based studies in health and demographic surveillance systems. Emerg Themes Epidemiol. 2012; 9(1): 8. PubMed Abstract | Publisher Full Text | Free Full Text

Ngugi AK, Bottomley C, Kleinschmidt I, et al.: Estimation of the burden of active and lifetime epilepsy: A meta-analytic approach. Epilepsia. 2010; 51(5): 883–890. PubMed Abstract | Publisher Full Text | Free Full Text

Ngugi AK, Bottomley C, Kleinschmidt I, et al.: Prevalence of active convulsive epilepsy in sub-Saharan Africa and associated risk factors: cross-sectional and case-control studies. Lancer Neurol. 2013; 12(3): 253–63. PubMed Abstract | Publisher Full Text | Free Full Text

Sadarangani M, Seaton C, Scott JA, et al.: Incidence and outcome of convulsive status epilepticus in Kenyan children: a cohort study. Lancet Neurol. 2008; 7(2): 145–50. PubMed Abstract | Publisher Full Text | Free Full Text

Thurman DJ, Beghi E, Begley CE, et al.: Standards for epidemiologic studies and surveillance of epilepsy. Epilepsia. 2011; 52 Suppl 7: 2–26. PubMed Abstract | Publisher Full Text
Open Peer Review

Current Peer Review Status:  

Version 2

Reviewer Report 25 July 2022

https://doi.org/10.21956/wellcomeopenres.19939.r51192

© 2022 Sun Y. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Yuelian Sun
Department of Neurology, Aarhus University Hospital, Aarhus, Denmark

I agreed with the author's arguments. However, the authors still use some strong words indicating 'causal inference' like 'Features and phenotypes of epilepsy in Africa may be determined by infections' in the conclusion, which could not be concluded from the findings of this study. Try to modify the words to reflect what the findings could show.

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Version 1

Reviewer Report 13 June 2022

https://doi.org/10.21956/wellcomeopenres.18830.r50872

© 2022 Tan H. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Hui Jan Tan
Department of Internal Medicine, Universiti Kebangsaan Malaysia Medical Centre (UKMMC), Kuala Lumpur, Malaysia

The article is well written and addresses the objectives succinctly. The authors provided good
analytical data for the work. The data presented provided valuable insight to the gravity of the problems encountered.

**Few comments:**
1. Was the multilogistic regression analysis done for the predictors?

2. Was there any active clinical infection for the seropositivity serology?

3. For the neurophysiology features: apart from focal seizures, was generalised seizures analysed?

**Is the work clearly and accurately presented and does it cite the current literature?**
Yes

**Is the study design appropriate and is the work technically sound?**
Yes

**Are sufficient details of methods and analysis provided to allow replication by others?**
Yes

**If applicable, is the statistical analysis and its interpretation appropriate?**
Yes

**Are all the source data underlying the results available to ensure full reproducibility?**
Yes

**Are the conclusions drawn adequately supported by the results?**
Yes

**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** epilepsy

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

---

Author Response 16 Jun 2022

**Symon Kariuki,** Kenya Medical Research Institute (KEMRI)/Wellcome Trust Research Programme, Kilifi, Kenya

The article is well written and addresses the objectives succinctly. The authors provided good analytical data for the work. The data presented provided valuable insight to the gravity of the problems encountered.

**Reply:** Thank you very much for positively appraising our manuscript. The useful concerns you raised are addressed below.

1. Was the multilogistic regression analysis done for the predictors?
Reply: Yes, a multivariable regression models were built, with all predictors, and exposure to infections as the response or outcome variable. Since exposure to infections was common in our sample, the odds ratios from a logistic regression model would overestimate the relative risks. This prompted use of multivariable modified Poisson regression models that produces accurate relative risks when outcomes are common in the population.

1. Was there any active clinical infection for the seropositivity serology?

Reply: The samples for these assays were collected when all participants reported to have been clinically well. However, it is possible that persistent exposure to the infections e.g. falciparum malaria could lead to active infections given that previous hospitalizations with clinical malaria was reported in 5.3% persons with epilepsy from the primary epidemiological study that generated these samples.

1. For the neurophysiology features: apart from focal seizures, was generalised seizures analysed?

Response: Both focal and generalized electroencephalographic seizures were documented. The analyses considers both focal and generalized electroencephalographic seizures, whereby the variables “focal seizures” has those with focal features coded as “1” and those with generalized features as “0”.

References
1. Ngugi AK, Bottomley C, Kleinschmidt I, et al. Prevalence of active convulsive epilepsy in sub-Saharan Africa and associated risk factors: cross-sectional and case-control studies. *The Lancet Neurology* 2013; 12(3): 253-63.
2. Kariuki SM, Matuja W, Akpalu A, et al. Clinical features, proximate causes, and consequences of active convulsive epilepsy in Africa. *Epilepsia* 2014; 55(1): 76-85.

Competing Interests: I have no competing interests to report.
The population consisted of 1,711 patients diagnosed with epilepsy in the five African countries. 997 patients were defined as respondents for test of infection. Respondents were tested for *Toxocara canis*, *Onchocerca volvulus*, *Plasmodium falciparum*, *Toxoplasma gondii*, HIV and *Taenia solium* (exposed). Infection status was determined through analysis of blood samples to detect antibodies to the infectious parasites and HIV. These assays to the infectious parasites and HIV were performed on 986 people with epilepsy.

The main concern of this study is that the authors might be unable to make causal inference (between parasitic infections and risk of epilepsy) using the data they had.

Although these parasitic infections could affect the central nervous system, they could not be defined as central nervous system (CNS) infections.

Even for a descriptive study, for example, parasitic infections among these epilepsy cases, the authors should be aware of the representativeness of the 1,711, response rate (why some cases responded and some did not), and differences among countries.

**Minor comments:**
- In the background of the abstract, should ‘epilepsy outcomes’ be ‘epilepsy outcomes’?
- Table 2. The total number, for example according to feature of focal seizure, is 996. How about those with missing value?

**Is the work clearly and accurately presented and does it cite the current literature?**
Yes

**Is the study design appropriate and is the work technically sound?**
No

**Are sufficient details of methods and analysis provided to allow replication by others?**
No

**If applicable, is the statistical analysis and its interpretation appropriate?**
No

**Are all the source data underlying the results available to ensure full reproducibility?**
No

**Are the conclusions drawn adequately supported by the results?**
No

**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** Epidemiologic research on risk factors, especially risk factors in early life for neurologic disorders, including epilepsy.
I confirm that I have read this submission and believe that I have an appropriate level of expertise to state that I do not consider it to be of an acceptable scientific standard, for reasons outlined above.

Author Response 16 Jun 2022

Symon Kariuki, Kenya Medical Research Institute (KEMRI)/Wellcome Trust Research Programme, Kilifi, Kenya

The authors aimed to examine if exposure to common central nervous system (CNS) infections may play a role in the early onset of epilepsy, convulsive status epilepticus, frequent seizures, abnormal electroencephalograph (EEG) findings, intellectual disabilities, neurological deficits as well as other medical comorbidities of epilepsy e.g. malnutrition.

The population consisted of 1,711 patients diagnosed with epilepsy in the five African countries. 997 patients were defined as respondents for test of infection. Respondents were tested for *Toxocara canis*, *Onchocerca volvulus*, *Plasmodium falciparum*, *Toxoplasma gondii*, HIV and *Taenia solium* (exposed). Infection status was determined through analysis of blood samples to detect antibodies to the infectious parasites and HIV. These assays to the infectious parasites and HIV were performed on 986 people with epilepsy.

The main concern of this study is that the authors might be unable to make causal inference (between parasitic infections and risk of epilepsy) using the data they had.

Response: Thank you for this important observation and agree that cross-sectional studies may not be useful in making causal inference, since the prevalence of seropositivity may vary if measured at a slightly different than when we did, and because it is difficult to pinpoint when the exposure occurred. However, cross-sectional studies, which easy and inexpensive, may be very useful generation of new or important hypothesis for understanding pathophysiology or prognosis or health conditions when this is not previously studied or understood. For instance, many previous studies only explored the etiological role of infections in development of new onset epilepsy, with no literature on how the persistent exposure after development of epilepsy changes the course of the disease, including even increasing the odds for severe disability and premature mortality. In addition, the analytical approach in this cross-sectional study aims at computing prevalence ratios that approximates relative risks in cohort studies, when outcomes are common and short-lived e.g. acute infections. Findings from this cross-sectional study are likely to inform set up of cohort studies to explore differential progression of epilepsy among persons exposed to infections, and to inform mass prophylaxis against exposure to infections among people already living with epilepsy. These observations are included in the statistical analysis section, limitations section and conclusion of the revised manuscript.

Although these parasitic infections could affect the central nervous system, they could not be defined as central nervous system (CNS) infections.

Response: We agree that some parasites e.g. *Onchocerca volvulus* might not directly affect the brain, but rather it is the inflammation provoked by the death of the parasite and the subsequent release of Wolbachia, for example, that may impact the
brain indirectly. We have therefore revised the term “central nervous system (CNS) infections” to “infections with a propensity for the central nervous system (CNS)”, which we hope is more acceptable.

Even for a descriptive study, for example, parasitic infections among these epilepsy cases, the authors should be aware of the representativeness of the 1,711, response rate (why some cases responded and some did not), and differences among countries.

**Response:** We agree that selection bias may be introduced by non-participation of participants. Some of those participated in the follow up evaluations may have had severe forms of epilepsy than those who dropped out, introducing severity bias which affect the associations that premised on severe forms of epilepsy as outcomes. Although there are many reasons for choosing not to participate in follow ups evaluations e.g. non-preference for biomedical facilities, other possibilities may be that some participants were unwell or even died, which can introduce survival bias. These possibilities are acknowledged in the limitation section of the revised manuscript.

**Minor comments:**
- In the background of the abstract, should ‘epilepsy foutcomes’ be ‘epilepsy outcomes’?

**Response:** Sorry for this typographical error, which has been revised as suggested.

- Table 2. The total number, for example according to feature of focal seizure, is 996. How about those with missing value?

**Response:** The variable “focal seizures” includes only those with these data, and therefore those with missing information are not included in the analysis.

**References**
1. Levin KA. Study design III: Cross-sectional studies. *Evidence-Based Dentistry* 2006; 7(1): 24-5.
2. Zou G. A modified poisson regression approach to prospective studies with binary data. *American journal of epidemiology* 2004; 159(7): 702-6.
3. Galán-Puchades MT. Onchocerciasis-associated epilepsy. *The Lancet Infectious Diseases* 2019; 19(1): 21-2.

**Competing Interests:** I do not have competing interests to declare.